Advanced Science (Jan 2022)

Soluble ICAM‐1 a Pivotal Communicator between Tumors and Macrophages, Promotes Mesenchymal Shift of Glioblastoma

  • Ki‐Chun Yoo,
  • Jae‐Hyeok Kang,
  • Mi‐Young Choi,
  • Yongjoon Suh,
  • Yi Zhao,
  • Min‐Jung Kim,
  • Jong Hee Chang,
  • Jin‐Kyoung Shim,
  • Seon‐Jin Yoon,
  • Seok‐Gu Kang,
  • Su‐Jae Lee

DOI
https://doi.org/10.1002/advs.202102768
Journal volume & issue
Vol. 9, no. 2
pp. n/a – n/a

Abstract

Read online

Abstract Despite aggressive clinical treatment, recurrence of glioblastoma multiforme (GBM) is unavoidable, and the clinical outcome is still poor. A convincing explanation is the phenotypic transition of GBM cells upon aggressive treatment such as radiotherapy. However, the microenvironmental factors contributing to GBM recurrence after treatment remain unexplored. Here, it is shown that radiation‐treated GBM cells produce soluble intercellular adhesion molecule‐1 (sICAM‐1) which stimulates the infiltration of macrophages, consequently enriching the tumor microenvironment with inflammatory macrophages. Acting as a paracrine factor, tumor‐derived sICAM‐1 induces macrophages to secrete wingless‐type MMTV integration site family, member 3A (WNT3A), which promotes a mesenchymal shift of GBM cells. In addition, blockade of either sICAM‐1 or WNT3A diminishes the harmful effect of radiation on tumor progression. Collectively, the findings indicate that cellular crosstalk between GBM and macrophage through sICAM‐1‐WNT3A oncogenic route is involved in the mesenchymal shift of GBM cells after radiation, and suggest that radiotherapy combined with sICAM‐1 targeted inhibition would improve the clinical outcome of GBM patients.

Keywords